Navigation Links
Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
Date:1/13/2014

SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio.

"We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move these programs forward and new positive interim data for tosedostat," said James A. Bianco, M.D. President and CEO of CTI. "We expect to continue that momentum with completion of the first of two Phase 3 clinical trials of pacritinib in myelofibrosis and potential topline data later in the year."

Progress Update

Pacritinib

  • In November 2013, CTI entered into a worldwide license agreement with Baxter International, Inc. (Baxter) to develop and commercialize pacritinib in which CTI and Baxter will jointly commercialize pacritinib in the United States and Baxter has exclusive commercialization rights for all indications outside the U.S.
  • The Phase 3 PERSIST-1 trial evaluating a broad set of myelofibrosis patients without limitations on blood platelet counts is currently enrolling patients. CTI expects to report topline data in the second half of 2014.
  • A second Phase 3 trial, PERSIST-2, in myelofibrosis patients with low platelet counts is expected to begin enrollment imminently. In October 2013, CTI reached agreement with the United States Food and Drug Administration (FDA) on a Special Protocol Assessment for this trial. This trial together with PERSIST-1 is intended to support registration in the U.S. and the Europea
    '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference
2. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
3. ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones
4. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
5. Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
6. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
7. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
8. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
9. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
10. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
11. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... Utah , Aug. 29, 2014  BC Technical, ... has acquired Polaris Medical Imaging, a leader in sales, ... This strategic acquisition allows BC Technical to continue to ... specifically within MR and CT modalities. ... service," said Mark Alvarez , president and CEO ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced ... dose-escalation study to evaluate the safety and tolerability of ... or Btk,as a potential treatment for patients with relapsed ... the first Btk selective inhibitor to,be tested in humans, ...
... MicroRNA-based Molecular Diagnostics to Mark Prometheus, Entry into ... and Development Funding plus Future RoyaltiesSAN DIEGO, PHILADELPHIA ... Inc., a specialty pharmaceutical and diagnostic company, and ... an innovative molecular diagnostic company, today announced the ...
Cached Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 3Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 4Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 6
(Date:8/31/2014)... 31, 2014 To make it easy ... they can trust, NutriGold is shipping complimentary samples of ... has been set up to make taking advantage of ... According to Priya Khan, Director of Research and Development ... one of our products, they are entrusting us with ...
(Date:8/31/2014)... Rockville, MD (PRWEB) August 31, 2014 ... electronic health records (EHR) software firm that focuses ... overall practice success found a congruent commitment with ... In Sports . , “We create an environment ... and effortlessly, allowing more time with patients,” says ...
(Date:8/31/2014)... Richmond, CA (PRWEB) August 31, 2014 ... program of the California State Library, celebrates 30 ... and their families. Since its inception, California’s Library ... a million Californians learn to read and write. ... this volunteer-based program, the state is launching a ...
(Date:8/31/2014)... Wine only protects against cardiovascular disease (CVD) in people ... Veritas (IVV) study presented at ESC Congress today by ... Taborsky said: "This is the first randomised trial comparing ... of atherosclerosis (1) in people at mild to moderate ... was only protective in people who exercised. Red and ...
(Date:8/30/2014)... A retrievable and repositionable transcatheter aortic valve is ... according to research presented at ESC Congress 2014 ... direct flow medical (DFM) transcatheter aortic valve has ... the potential to improve transcatheter aortic valve implantation ... , Dr Pyxaras said: "TAVI is well established ...
Breaking Medicine News(10 mins):Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Wine only protects against CVD in people who exercise 2Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2
... Reporter , MONDAY, May 28 (HealthDay News) -- Updated ... good news for those at risk of osteoporosis, but ... other chronic diseases. While estrogen-only and estrogen-plus-progestin formulations ... for stroke and other conditions including gallbladder disease, according ...
... study suggests that aspirin and other similar painkillers may ... CANCER , a peer-reviewed journal of the American ... may be added to the benefits of these commonly ... anti-inflammatory drugs, or NSAIDs, which include aspirin, ibuprofen, and ...
... Reporter , MONDAY, May 28 (HealthDay News) -- Sensory ... increasingly used by occupational therapists to treat children with ... organization says there isn,t much evidence that such therapies ... the potential of sensory therapies -- it,s a ripe ...
... -- Picnics, parades and cookouts are as much a part ... war veterans. But, before tucking into that leafy, green ... vegetables can become contaminated with harmful pathogens that cause food ... listeria and norovirus, according to the Academy of ...
... -- Boosting students, levels of physical education improves their ... followed more than 200 schoolchildren, starting from first through ... to an intervention group that received physical education five ... such as balance and coordination. The other children were ...
... , FRIDAY, May 25 (HealthDay News) -- People ... colitis, may be at increased risk for flare-ups when ... or mountain climbing, a new study suggests. This ... involves the small intestine) or ulcerative colitis (which typically ...
Cached Medicine News:Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 2Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 3Health News:Commonly used painkillers may protect against skin cancer 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 3Health News:Keep Food Safety in Mind This Memorial Day Weekend 2Health News:Travel to High Altitudes Tied to Crohn's, Colitis Flare-Ups 2
... Monitor (PCM) and Central Station provide an ... extends the cardiac cath or electrophysiology lab ... and/or EP procedures, providing both physiomonitoring parameters ... either standalone or on its own network. ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
... Gemini Family of infusion pumps ... a collective series of administration ... line offers a wide variety ... sets, each featuring the patented ...
Medicine Products: